Figure 2. B lymphocytes are required for anti–TIM-1–mediated prolongation of allograft survival.
(A) Chemically diabetic BALB/c mice were untreated or subjected to B cell depletion with anti-CD20 (250 μg i.v. on days –14 and –1) followed by transplantation with B6 islets. Allograft recipients were either untreated or treated with RMT1-10 or control Ig at 0.5 mg (day –1) and 0.3 mg (days 0 and 5). (B) JHD mice were unmanipulated or received 107 WT syngeneic B cells followed by transplantation with B6 islets (day 0). Allograft recipients were treated as in A. Shown are Kaplan-Meir plots of graft survival. *P < 0.05, **P < 0.01 vs. untreated or control Ig; #P < 0.05 vs. other anti-CD20 groups; †P < 0.01 vs. B cells.